Patients who are receiving any ot her investigational agents. SCREENING EVALUATION Note : Testing for screening evaluation is conducted under the NCI S B companion protocol, 99- C-0128 (Evaluation for NCI Surgery Branch Clinical Research Prot ocols). Note : The date of enrollment is the date the subject signs the writt en informed consent document. The patient will be c onsented and enrolled on this prot ocol once the patient has adequate leukapheresi s material banked by the Surgery Branch Ce ll Production Facility (SB CPF) and prior to administr ation of the first vaccine. 2.2.1 Within 3 Months Prior to Enrollment xHIV antibody titer, HBsAg determination, and anti HCV xConfirmation of diagnosis of metas tatic melanoma or epithelial cancer by the Laboratory of Pathology of NCI. (Note: T esting is permitte d to be conducte d at any time prior to enrollment.) xAnti CMV antibody titer, HSV ser ology, and EBV panel. (Note: Pa tients who are known to be positive do not nee d to be retested.) 2.2.2 Within 4 Weeks Prior to Enrollment xComplete history and physical exa mination. (Note: Patient history may be obtained within 8 weeks prior to enrollment.) xBaseline imaging to determine the status of disease. This may include CT, MRI, PET, and/or photography. 2.2.3 Within 7 Days Prior to Enrollment xPhysical examination, including ECOG of 0, 1, or 2 xVital signs xCBC w/differential xAcute Care Panel (sodium, potassium, chloride, bicarbonate, cre atinine, glucose, BUN), Hepatic Panel (alkaline phosphat ase, AST/GOT, ALT/GPT, total bilirubin, direct bilirubin), Mineral Panel (al bumin, calcium, magnesium, phospho rus), Uric Acid, Creatinine Kinase, Lactate Dehydrogenase, Total Protein xPT/PTT xȕ-HCG pregnancy test (serum or urine) on all females of child-bea ring potential xUrinalysis, with culture if indicated xChest x-ray xEKG Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 15 REGISTRATION PROCEDURES 2.3.1 Prior to Registra tion for this Protocol Patients will initiall y sign the consent for and enroll on the NC I SB companion protocol, 03-C- 0277 (Cell Harvest and Preparati on for Surgery Branch Adoptive Cell Therapy Protocols), prior to tumor harvest and leukapheresi s for generation of the cell p roduct. Patients will sign the consent for and enroll on this t reatment protocol once the patient has adequate leukapheresis material banked by the SB CPF a nd prior to administration of the first vaccine. Immature and mature dendritic ce lls must pass the FACS and ster ility or gram stain assay as noted in the Certificates of Analysis (CoAs) ( Appendix 2 and Appendix 3 ). If cells do not meet CoA requirements then the patient will be taken off-study (Sect ion 3.6.2). Once it is confirmed that immature and matur e dendritic cells have met the CoA requirements ( Appendix 2 and Appendix 3 ), the vaccines will be ad ministered to the patient. 2.3.2 Registration Procedure Authorized staff must register an eligible candidate with NCI C entral Registration Office (CRO) within 24 hours of signing consen t. A registration Eligibility Checklist from the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via encrypted email to: NCI Central Registration Office at ncicentra lregistration-l@mail.nih.gov. After confirmation of eligibility at Central Registration Offic e, CRO staff will call pharmacy to advise them of the acceptan ce of the patient on the protocol pr ior to the release of any investigational agents. Verifi cation of Registr ation will be fo rwarded electronically via email to the research team.